Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells. Blocking the activity of a5ß1 integrin has been found to prevent angiogenesis, which is the formation of new blood vessels that feed tumors and allow them to grow and metastasize. We believe that volociximab may have potential in treating solid tumors and that its role in angiogenesis may also be applicable in ophthalmic indications.

Volociximab is currently in clinical development for non-small cell lung cancer (NSCLC). In the past, we have conducted studies of volociximab in ovarian cancer, pancreatic cancer, renal cell carcinoma and melanoma. The data from these trials and associated analyses have contributed to our understanding of the mechanism of action and safety profile of volociximab, and we are applying this knowledge to our development program. We plan to continue to evaluate the data from our current study and collaborate with our partner, Biogen Idec, to determine future development plans for this antibody.

We have a worldwide strategic development collaboration for volociximab with Biogen Idec in which we share development costs and commercial rights in all indications. We and Biogen Idec have licensed volociximab for ophthalmic indications to Ophthotech Corporation for various milestones and eventual royalties on potential product sales.

Please visit our volociximab publications page to view our most recent data presentations for this program.

For inquiries about our clinical trials, please call our information line at 650 454-1400 or visit the National Institutes of Health website (http://www.clinicaltrials.gov).